Toxicity management of Immunotherapy Drugs

The unique side effects of checkpoint inhibitors are uniformly termed as immune-related adverse events (irAEs). These include a range of mainly dermatologic, gastrointestinal (GI), endocrine and hepatic toxicities, as well as several other less common inflammatory events. All these adverse events have variable times of onset, they have an autoimmune etiology and they need careful monitoring, follow-up and management. With appropriate and timely treatment, these toxicities are usually reversible, but they can become severe and even life-threatening if they are not recognized early enough. These checkpoint inhibitor side effects are reviewed here and their management is presented based on clinical experience and published guidelines, algorithms and recommendations, which refer mainly to the knowledge obtained from the use of ipilimumab.

 

    Related Conference of Toxicity management of Immunotherapy Drugs

    Toxicity management of Immunotherapy Drugs Conference Speakers